What We Do

  • Identify non-dilutive capital sources from local, state, and federal institutions—including CPRIT (Cancer Prevention Research Institute of Texas) and SBIR.
  • Help clients leverage early-stage non-dilutive capital to reach key development milestones that support higher valuations in later financing rounds.
  • Guide and support clients through the full application process, implementing best practices to increase the likelihood of successful awards.

Achievements 2016-2021

  • Secured $50M+ of awards from the Cancer Prevention Research Institute of Texas (CPRIT) resulting in the advancement of drug programs through pre / clinical studies
  • SJA worked closely with a Chicago-based gene therapy company, Inomagen Therapeutics, securing a $3.67M NIH / SBIR Fast Track award funding the company through IND